secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001077183-25-000172
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M
-------------------------------------------------------------------

- Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.
- Net loss $27M vs $18M, up 53%; adjusted EBITDA $12.2M, down 9% from $13.4M.
- Reaffirmed FY 2025 guidance: revenue $720-726M, net loss $(116)-(108)M, adj EBITDA $41-44M.
- OpEx +12% YoY, includes $7.1M impairment charge on Trapelo held-for-sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000172/0001077183-25-000172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718325000172/neo-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001077183-25-000172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer